Ilya Pharma, a clinical stage immunotherapy company, has closed a €8.5 million funding round, which will be used to advance the company’s portfolio of three first-in-class immunotherapies for skin and mucosal diseases.
The portfolio
The active portfolio includes ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic ulcers and ILP100-Oral for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors.
Official comments
Evelina Vågesjö, CEO and Co-Founder of Ilya Pharma, said: “We are happy to be able to announce the completion of the transaction and to have the EIC Fund on board. Although they are a major player in Europe at the moment, they have only just started making direct investments in growth stage SMEs. We would also like to thank all investors for their cooperation and contributing to developing the company to our next stage of growth. We continue maintain a high pace and are actually already securing new industrial investors to our recently opened Series B round, welcoming those interested in particular in innovative and de-risked clinical programmes. In parallel we have started to plan for a public listing of the share in 2024 coinciding with the clinical data readouts of our lead programmes.”
